GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Astrazeneca Pharma India ASTRAZEN.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

6,514.50

+2.21%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2025

Revenue

₹17.16bn

FY2016FY2025

Net income

₹1.16bn

FY2016FY2025

Free cash flow

₹636.1m

FY2016FY2025

Shareholders' equity

₹7.70bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₹17.16bn₹12.96bn₹10.03bn₹8.06bn₹8.14bn₹8.32bn₹7.28bn₹5.72bn₹5.49bn₹5.64bn
Gross profit₹7.10bn₹6.17bn₹5.72bn₹4.40bn₹4.76bn₹4.90bn₹4.50bn₹3.39bn₹3.34bn₹3.41bn
Operating income₹1.18bn₹1.87bn₹1.09bn₹693.6m₹1.16bn₹1.03bn₹565.7m₹323.0m₹220.1m−₹2.1m
Net income₹1.16bn₹1.62bn₹992.9m₹616.0m₹933.0m₹722.1m₹544.5m₹259.1m₹200.5m₹52.6m
Diluted earnings per share46.3164.6039.7224.6437.3428.8821.7810.378.022.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₹15.18bn₹10.78bn₹9.85bn₹8.57bn₹7.75bn₹7.06bn₹5.62bn₹4.61bn₹4.15bn₹4.49bn
Cash and short-term investments₹5.36bn₹5.06bn₹5.00bn₹4.49bn₹3.52bn₹2.52bn₹1.73bn₹1.26bn₹1.15bn₹768.1m
Total liabilities₹7.48bn₹3.66bn₹3.96bn₹3.45bn₹3.19bn₹3.42bn₹2.61bn₹2.14bn₹1.93bn₹2.45bn
Debt₹294.5m₹27.8m₹36.9m₹50.2m₹86.3m₹93.0m————
Shareholders' equity₹7.70bn₹7.12bn₹5.89bn₹5.11bn₹4.56bn₹3.64bn₹3.01bn₹2.47bn₹2.23bn₹2.03bn
Shares outstanding25m25m25m25m25m25m25m25m25m25m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations₹653.6m₹278.7m₹582.9m₹1.01bn₹1.05bn₹874.2m₹549.8m₹87.9m₹381.0m₹569.9m
Capital spending−₹17.5m−₹107.6m−₹85.2m−₹96.2m−₹77.1m−₹142.2m−₹186.9m−₹62.8m−₹56.5m−₹90.4m
Free cash flow₹636.1m₹171.1m₹497.7m₹911.8m₹970.7m₹732.0m₹362.9m₹25.1m₹324.5m₹479.4m
Dividends paid−₹600.0m−₹400.0m−₹200.0m−₹50.0m−₹50.0m−₹25.0m————

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue₹6.12bn₹5.59bn₹5.26bn₹4.80bn₹4.40bn₹4.08bn₹3.88bn₹3.83bn
Gross profit₹2.45bn₹2.35bn₹2.31bn₹2.21bn₹1.93bn₹1.82bn₹1.57bn₹1.70bn
Operating income₹424.7m₹673.2m₹641.8m₹630.0m₹343.7m₹432.0m₹342.0m₹456.0m
Net income₹325.9m₹542.2m₹558.3m₹582.5m₹308.5m₹384.3m−₹118.0m₹395.0m
Diluted earnings per share13.0421.6922.3423.3112.3415.37-4.7215.80
Cash from operations—−₹657.0m—₹653.0m—₹384.0m—₹278.0m
Capital spending—−₹2.0m—−₹17.0m—−₹7.0m—−₹107.0m
Free cash flow—−₹659.0m—₹636.0m—₹377.0m—₹171.0m
Total assets—₹16.15bn—₹15.18bn—₹12.41bn—₹10.78bn
Cash and short-term investments—₹4.10bn—₹5.36bn—₹5.08bn—₹5.06bn
Debt—₹278.8m—₹294.5m—₹133.3m—₹27.8m
Shareholders' equity—₹7.99bn—₹7.70bn—₹6.79bn—₹7.12bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue28.7%15.6%13.9%
Operating income19.2%2.8%—
Net income23.4%9.9%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin44.1%48.5%51.1%53.9%
Operating margin10.1%10.0%10.8%8.4%
Net margin9.2%9.1%9.3%7.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings194.4111.8139.2133.682.9160.0120.0139.9144.8437.4
Price to sales13.113.913.810.29.513.99.06.35.34.1

Dividends and splits

Per share, in the currency the company pays

Paid for 7 years. Last went ex-dividend on 31 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2013
Paid in the year32.0024.0016.008.002.002.001.003.50
  • 10-for-2 split · 15 Jun 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.